Source: Annual Congress 2013 –Biomarkers in asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Tam, S. J. Um, H. Coxson, S. Lam, S. Man, D. Sin (Vancouver, Canada). Pro-surfactant protein B, a promising BAL biomarker of COPD progression in heavy smokers, is increased by budesonide/formoterol short-term therapy. Eur Respir J 2013; 42: Suppl. 57, 397

Member's Comments

No comment yet.

Related content which might interest you: What is the best biomarker of COPD stability? Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015 Role of inflammatory biomarkers in COPD Source: International Congress 2016 – Systemic biomarkers Year: 2016 Serum BNP levels in COPD, asthma-COPD-overlap-syndrome, smokers and never-smokers Source: International Congress 2016 – Systemic biomarkers Year: 2016 Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015 Sputum biomarkers of inflammation in smokers and subjects with COPD Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014 Altered expression of glycosaminoglycans in the BAL of COPD patients with acute exacerbation Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench Year: 2013 Endothelial microparticles in sputum of COPD patients: A potential biomarker of disease Source: International Congress 2015 – Systemic and airway biomarkers Year: 2015 Pharmacodynamic effect of benralizumab on blood basophils and serum biomarkers in adults with COPD with sputum eosinophilia Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 The prognostic value of cardiac and inflammatory biomarkers in acute exacerbations of COPD Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 COPD Source: Respipedia Article Year: 2018 Serum sirtuin-1 is reduced in COPD Source: International Congress 2016 – Systemic biomarkers Year: 2016 Microarray profiling of COPD patients versus non-COPD smokers reveals possible disease biomarkers Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 L-arginine pathway metabolites can predict exacerbation independently from beta blocker treatment in patients with COPD: A follow-up study Source: International Congress 2016 – Systemic biomarkers Year: 2016 Fibrinogen and CRP biomarkers in patients with exacerbation of COPD group C and D Source: International Congress 2014 – Systemic biomarkers for airway diseases Year: 2014 Increased circulating alveolar epithelial microparticles in COPD patients Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Changes of IL-6 level in bronchoalveolar fluid in patients with acute exacerbation of COPD before and after the treatment with tiotropium bromide, and its significance Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013 Alterations of the soluble proteome of airway epithelial cells in COPD Source: Annual Congress 2013 –New strategies in epigenomic research to study lung diseases (DNA rearrangements, RNA, methylation, proteosome) Year: 2013 Biomarkers in COPD exacerbation, the role of adiponectin Source: International Congress 2014 – Predictors Year: 2014 COPD: Plasma surfactant protein-D (SPD) concentration as a predictor of acute exacerbations (AE) probability Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016